AVALON PHARMACEUTICALS INC Contracts & Agreements
115 Contracts & Agreements
- Business Finance (21 contracts)
- Business Operations (7)
- Human Resources (9)
- Intellectual Property (2)
- Mergers & Acquisitions (3)
- Uncategorized (73)
- SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (Filed With SEC on April 2, 2009)
- FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT (Filed With SEC on April 2, 2009)
- AMENDMENT NO. 2 (Filed With SEC on April 2, 2009)
- TERM NOTE $1,000,000 March 30, 2009 (Filed With SEC on April 2, 2009)
- FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (Filed With SEC on January 14, 2009)
- AMENDMENT NO. 1 (Filed With SEC on January 14, 2009)
- AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (Filed With SEC on October 30, 2008)
- FORM OF CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on October 30, 2008)
- Amendment No. 1 to Rights Agreement (Filed With SEC on October 30, 2008)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on October 30, 2008)
- COMMON STOCK PURCHASE WARRANT (Filed With SEC on October 30, 2008)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 30, 2008)
- AVALONRX LICENSE AGREEMENT (Filed With SEC on October 30, 2008)
- AVALON PHARMACEUTICALS, INC. (Filed With SEC on October 30, 2008)
- FORM OF TERM NOTE $3,000,000 October 27, 2008 (Filed With SEC on October 30, 2008)
- INTELLECTUAL PROPERTY SECURITY AGREEMENT (Filed With SEC on October 30, 2008)
- SEVERANCE AGREEMENT AND RELEASE (Filed With SEC on May 8, 2008)
- Fourth Addendum to Consulting Agreement Dated February 1, 2000 (Filed With SEC on March 31, 2008)
- Fifth Addendum to Consulting Agreement Dated February 1, 2000 (Filed With SEC on March 31, 2008)
- Amendment No. 6 to CONSULTING AGREEMENT By and Between Avalon Pharmaceuticals, Inc. and Bradley G. Lorimier (Filed With SEC on March 31, 2008)
- THIRD MODIFICATION AGREEMENT (Filed With SEC on March 31, 2008)
- FOURTH MODIFICATION AGREEMENT (Filed With SEC on February 15, 2008)
- AVALON PHARMACEUTICALS, INC. 2005 OMNIBUS LONG-TERM INCENTIVE PLAN TABLE OF CONTENTS (Filed With SEC on June 7, 2007)
- PURCHASE AGREEMENT (Filed With SEC on May 29, 2007)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 29, 2007)
- AVALON PHARMACEUTICALS, INC. WARRANT (Filed With SEC on May 29, 2007)
- PURCHASE AGREEMENT (Filed With SEC on May 14, 2007)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 14, 2007)
- EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between MERCK & CO., INC. and AVALON PHARMACEUTICALS, INC. (Filed With SEC on May 14, 2007)
- [LETTERHEAD] [LOGO] May 2, 2007 (Filed With SEC on May 4, 2007)
- [LETTERHEAD] [LOGO] (Filed With SEC on May 4, 2007)
- RIGHTS AGREEMENT Dated as of April 26, 2007 between AVALON PHARMACEUTICALS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY 1 TABLE OF CONTENTS (Filed With SEC on April 30, 2007)
- Exhibit 10.6B (Filed With SEC on March 30, 2007)
- Exhibit 10.7B (Filed With SEC on March 30, 2007)
- Exhibit 10.8B (Filed With SEC on March 30, 2007)
- Exhibit 10.9B (Filed With SEC on March 30, 2007)
- Exhibit 10.10 (B) (Filed With SEC on March 30, 2007)
- Exhibit 10.11B (Filed With SEC on March 30, 2007)
- risks relating to the early stage of product candidates under development (Filed With SEC on March 30, 2007)
- COLLABORATION AGREEMENT between AVALON PHARMACEUTICALS, INC. and CHEMDIV, INC. (Filed With SEC on November 8, 2006)
- FIRST AMENDMENT TO COLLABORATION AGREEMENT (Filed With SEC on November 8, 2006)
- Exhibit 10.1 (Filed With SEC on August 2, 2006)
- Fourth Addendum to Consulting Agreement Dated February 1, 2000 (Filed With SEC on April 7, 2006)
- Exhibit 10.1 PURCHASE AGREEMENT (Filed With SEC on March 3, 2006)
- Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 3, 2006)
- Exhibit 10.1 Stock Election Policy for Non-Employee Director Fees (Filed With SEC on December 5, 2005)
- AVALON PHARMACEUTICALS, INC. 2005 OMNIBUS LONG-TERM INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on November 1, 2005)
- AVALON PHARMACEUTICALS, INC. 2005 OMNIBUS LONG-TERM INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT (Filed With SEC on November 1, 2005)
- Pilot Study Agreement (Filed With SEC on September 14, 2005)
- [2,750,000] Shares AVALON PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on September 9, 2005)
- Avalon Pharmaceuticals, Inc. (Filed With SEC on September 9, 2005)
- LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Vertex Pharmaceuticals Incorporated and Avalon Pharmaceuticals, Inc. (Filed With SEC on September 9, 2005)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on September 9, 2005)
- COLLABORATION AGREEMENT (Filed With SEC on September 9, 2005)
- EXECUTION COPY CONFIDENTIAL COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on September 9, 2005)
- AVALON PHARMACEUTICALS, INC. AMENDED AND RESTATED LINE OF CREDIT AGREEMENT (Filed With SEC on September 9, 2005)
- AMENDED AND RESTATED MODIFICATION AND CONSENT AGREEMENT (Filed With SEC on August 18, 2005)
- SECOND MODIFICATION AGREEMENT (Filed With SEC on August 18, 2005)
- AVALON PHARMACEUTICALS INC. 2005 OMNIBUS LONG-TERM INCENTIVE PLAN (Filed With SEC on August 18, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on June 23, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on June 23, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)
- develop our anticancer therapeutic candidates (Filed With SEC on May 3, 2005)